OncoMatch/Gastric / Stomach Cancer/MMR / MSI-H
Gastric / Stomach CancerMMR / MSI-H Clinical Trials
Mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) occurs in approximately 4–8% of advanced gastric cancers and defines a highly immunotherapy-sensitive subgroup. Pembrolizumab achieved tumor-agnostic FDA approval for dMMR/MSI-H solid tumors, and nivolumab combinations are approved in the first-line setting. Trials study neoadjuvant immunotherapy for locally advanced MSI-H gastric cancer, checkpoint combinations, and MRD-guided surgery approaches.
Top recruiting MMR / MSI-H Gastric / Stomach Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
ECOG-ACRIN Cancer Research Group
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Peking University Third Hospital
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Peking University
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer
Shanghai Zhongshan Hospital
More MMR / MSI-H Gastric / Stomach Cancer trials
4 international trials (no US sites)
Browse other molecular targets with active Gastric / Stomach Cancer trials.